Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263692 · ClinicalTrials.gov registry record · Phase 2
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 401
- Enrollment target
NCT00263692 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 401 participants.
The verdict
NCT00263692, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 401 participants
- Enrollment target
Study Summary
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis vaccine to children aged 4 to 6 years when co-administered with MMR vaccine in subjects who had previously received four doses of Infanrix, three doses of poliovirus-containing vaccine and MMR vaccination.
Interventions
- BIOLOGICAL Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263692
The ClinicalTrials.gov registry entry for NCT00263692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3 is the first listed.
NCT00263692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00263692 about?
NCT00263692 is a clinical study titled "Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety". The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis vaccine to children aged 4 to 6 years when co-administered with MMR va...
What is the current status of trial NCT00263692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 401 participants. The study started on 2002-11. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00263692?
The interventions under investigation include: Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00263692?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.